Diabetes cell therapy - Living Cell Technologies

Drug Profile

Diabetes cell therapy - Living Cell Technologies

Alternative Names: DiabeCell

Latest Information Update: 25 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Living Cell Technologies
  • Developer Diatranz Otsuka Limited; Living Cell Technologies
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 25 Mar 2015 Phase II development is ongoing New Zealand
  • 25 Mar 2015 No recent reports of development identified - Registered for Type-1 diabetes mellitus in Russia (Intraperitoneal)
  • 05 Mar 2015 Diatranz Otsuka Limited and Otsuka Pharmaceutical agree to co-develop and commercialise Diabetes cell therapy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top